LB Pharmaceuticals 3Q 2026: EPS ($1.79) — 10-Q Summary

LB Pharmaceuticals reported a wider third-quarter net loss year over year as research and development spending rose sharply, primarily from its Phase 3 schizophrenia trial, and general and administrative costs increased. Higher interest income partly offset the expense growth.Financial Highlights²…